Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study

Yoshihisa Ishiura; Masaki Fujimura; Noriyuki Ohkura; Johsuke Hara; Kahori Nakahama; Yusuke Sawai; Takeshi Tamaki; Ryuta Murai; Toshiki Shimizu; Naoyuki Miyashita; Shosaku Nomura

doi:10.2147/JAA.S360260

Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study

J Asthma Allergy. 2022 May 23:15:703-712. doi: 10.2147/JAA.S360260. eCollection 2022.

Affiliations

¹ First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
² Respiratory Medicine, National Hospital Organization Nanao Hospital, Nanao, Japan.
³ Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.

Abstract

Purpose: The 'treatable traits' strategy for patients with chronic inflammatory airway diseases, especially asthma and chronic obstructive pulmonary disease (COPD), is a focus of interest, because it implements precision and personalized medicine. Asthma-COPD overlap (ACO), a phenotype involving both asthma and COPD, is an important disease entity because patients with ACO have significantly worse outcomes, conferring greater economical and social burdens. Some guidelines for ACO recommend add-on therapy of long-acting muscarinic antagonists to inhaled corticosteroids and long-acting β₂ agonists. However, this approach is based on extrapolation from patients with asthma or COPD alone. Consequently, a 'treatable traits' approach suitable for ACO remains obscure.

Methods: A 12-week open-label cross-over pilot study was conducted in patients with ACO to investigate the effect of tiotropium bromide (TIO) 5 µg/day add-on therapy to fluticasone propionate/formoterol fumarate (FP/FM) 500/20 µg/day compared with FP/FM 500/20 µg/day alone. A 4-week run-in period and two 4-week treatment periods were included.

Results: A total of 18 male patients with stable ACO participated in this pilot study. All patients were ex-smokers. Mean values ± standard deviation (SD) for forced expiratory volume in 1 second (FEV₁) were 1.21 ± 0.49 L after the run-in period, 1.20 ± 0.51 L after the FP/FM combination therapy period, and 1.30 ± 0.48 L after the TIO add-on therapy to FP/FM period. FEV₁ values after the TIO add-on therapy FP/FM period were significantly higher than those after the run-in period (p < 0.01).

Conclusion: TIO add-on therapy to FP/FM in patients with ACO, considered difficult to treat because of the presence of both asthma and COPD, resulted in improvements in lung function parameters in this real-world pilot study, indicating the potential value of TIO add-on therapy as a "treatable traits" option for standard treatment for ACO.

Keywords: asthma-COPD overlap; fluticasone; formoterol; tiotropium; treatable trait; triple therapy.